TOP-507-YI Single-cell RNA sequencing-derived gene signatures reveal distinct response mechanisms to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

Sarah Cappuyns; Marta Piqué‐Gili; Roger Esteban-Fabró; Gino Philips; Roser Pinyol; Albert Gris‐Oliver; Vincent Vandecaveye; Jordi Abril‐Fornaguera; Carla Montironi; Laia Bassaganyas; Judit Peix; Marcus Zeitlhoefler; Agavni Mesropian; Júlia Huguet‐Pradell; Philipp K. Haber; Rephael Mohr; Tim Meyer; Helen L. Reeves; Julien Edeline; Fabian Finkelmeier; Jörg Trojan; Peter R. Galle; Friedrich Foerster; Beatriz Mínguez; Robert Montal; Mathias Heikenwälder; Chris Verslype; Eric Van Cutsem; Diether Lambrechts; Augusto Villanueva; Jeroen Dekervel; Josep M. Llovet

doi:10.1016/s0168-8278(24)01319-9

Shared by

Josep M. Llovet

TOP-507-YI Single-cell RNA sequencing-derived gene signatures reveal distinct response mechanisms to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

Journal of Hepatology 80: S411-S412

Article 2024 Unknown la

Authors

SC
Sarah Cappuyns
MP
Marta Piqué‐Gili
RE
Roger Esteban-Fabró

Abstract

1 min read

No abstract is provided for this article.

Related publications

Article2023

Predicting response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma using single-cell RNA-sequencing-derived gene signatures

Sarah Cappuyns, Marta Piqué‐Gili, Roger Esteban-Fabró, Gino Philips, Roser Pinyol, Vincent Vandecaveye, Jordi Abril‐Fornaguera, Philipp K. Haber, Chris Verslype, Eric Van Cutsem, Diether Lambrechts, Augusto Villanueva, Jeroen Dekervel, Josep M. Llovet

Journal of Hepatology

Article2024

Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

Sarah Cappuyns, Marta Piqué‐Gili, Roger Esteban-Fabró, Gino Philips, Ugne Balaseviciute, Roser Pinyol, Albert Gris‐Oliver, Vincent Vandecaveye, Jordi Abril‐Fornaguera, Carla Montironi, Laia Bassaganyas, Judit Peix, Marcus Zeitlhöfler, Agavni Mesropian, Júlia Huguet‐Pradell, Philipp K. Haber, Igor Figueiredo, Giorgio Ioannou, Edgar Gonzalez‐Kozlova, Antonio D’Alessio, Raphael Mohr, Tim Meyer, Anja Lachenmayer, Jens U. Marquardt, Helen L. Reeves, Julien Edeline, Fabian Finkelmeier, Jörg Trojan, Peter R. Galle, Friedrich Foerster, Beatriz Mínguez, Robert Montal, Sacha Gnjatic,

Journal of Hepatology

Letter2023

Atezolizumab Plus Bevacizumab in Advanced HCC: Efficacy in NASH-Specific Etiology

Josep M. Llovet, Mathias Heikenwälder

Gastroenterology

Letter2011

Hepatocellular Carcinoma Enters the Sequencing Era

Augusto Villanueva, Yujin Hoshida, Josep M. Llovet

Gastroenterology

Article2025

Single Cell RNA and Whole Genome Sequencing Analysis Reveal Distinct Immune and Genomic Signatures in WM Patients Resistant to Ibrutinib Therapy

Tina Bagratuni, Christos Vlachos, Μαρία Σάκκου, Ioannis Kollias, Ourania Theologi, Nefeli Mavrianou Koutsoukou, Christine‐Ivy Liacos, Alexandra Papadimou, Kostantina Taouxi, Katerina Chrisostomidou, Despina Fotiou, Evangelos Terpos, Efstathios Kastritis, Meletios A Dimopoulos

TOP-507-YI Single-cell RNA sequencing-derived gene signatures reveal distinct response mechanisms to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

Abstract

Discussion(0)

Related publications

Predicting response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma using single-cell RNA-sequencing-derived gene signatures

Single-cell RNA seq-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

Atezolizumab Plus Bevacizumab in Advanced HCC: Efficacy in NASH-Specific Etiology

Hepatocellular Carcinoma Enters the Sequencing Era

Single Cell RNA and Whole Genome Sequencing Analysis Reveal Distinct Immune and Genomic Signatures in WM Patients Resistant to Ibrutinib Therapy